2 registrations that name pterostilbene as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT07579429
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Phase 2
University of Colorado, Denver
About 10 people
Started May 20, 2026
In plain words A Phase 2 study of pterostilbene in people 18 and older, run by University of Colorado, Denver. It plans to enroll about 10 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Clonal Cytopenia of Undetermined Significance; Myelodysplastic Syndrome.
Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed procedures.
Stated willingness to comply with all study procedures and be available for the duration of the study.
Be a male or female aged ≥ 18 years of age.
For persons of reproductive potential, use of highly effective method(s) of contraception.
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside; Pterostilbene
Registered summary
This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are: * to assess if study drug improves cytopenias in patients * to determine safety of the study drug in patients
Where, as registered
1 US site in 1 state.
RecruitingNCT07024966
Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress
No phase
Fundació Eurecat
About 14 people
Started Aug 1, 2025
In plain words A study of pterostilbene in male participants 18 to 50, run by Fundació Eurecat. It plans to enroll about 14 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 50; healthy volunteers accepted. Conditions: Oxidative Stress; Physical Activity; Antioxidant Effect.
Male participants between 18 and 50 years of age who are amateur runners.
Engage in at least 3 continuous running sessions per week, each lasting 60 minutes, which corresponds to a high level of physical activity according to the International Physical Activity Questionnaire (IPAQ).*
Self-report being able to continuously run for 45 minutes at high intensity without difficulty.
Provide signed informed consent prior to participation in the study.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Pterostilbene-silybin-nicotinamide riboside; Control Group
Registered summary
This study aims to evaluate the effects of the dietary supplement ccPT-SIL-NR, which contains pterostilbene (ccPT), silybin (SIL), and nicotinamide riboside (NR), on oxidative stress markers after a high-intensity exercise session. The primary objective is to assess changes in blood malondialdehyde (MDA) levels. The full summary is on the listing.